PURE - PURE Bioscience, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.4020
-0.0030 (-0.74%)
At close: 2:40PM EST
Stock chart is not supported by your current browser
Previous Close0.4050
Open0.4000
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.4000 - 0.4100
52 Week Range0.2900 - 0.9500
Volume14,834
Avg. Volume37,700
Market Cap28.829M
Beta (3Y Monthly)0.09
PE Ratio (TTM)N/A
EPS (TTM)-0.111
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents15 days ago

    Edited Transcript of PURE earnings conference call or presentation 13-Dec-18 9:30pm GMT

    Q1 2019 PURE Biosciences Inc Earnings Call

  • Business Wirelast month

    PURE Bioscience Reports Fiscal 2019 Q1 Financial Results

    Commercialization Updates on PURE Control® and PURE® Hard Surface Antimicrobial Food Safety Solutions

  • Business Wire2 months ago

    PURE Bioscience Sets Fiscal 2019 Q1 Financial Results Conference Call

    PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial, announced today that on December 13, 2018 the Company will file its Form 10-Q shortly after the close of the market and will host an investor conference call that day at 1:30 p.m. PT (4:30 p.m. ET) to review fiscal 2019 Q1 financial results. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds.

  • Business Wire2 months ago

    PURE Bioscience to Present at the 11th Annual LD Micro Conference

    PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial, today announced that Hank R. Lambert, CEO, will present at the 11th Annual LD Micro Conference on Wednesday, December 5th at 11:00 am PT, at the Luxe Hotel Sunset Boulevard in Los Angeles. The presentation will be webcast live and slides may be accessed on the Company's website, http://www.purebio.com/investors/events-presentations/.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of PURE earnings conference call or presentation 25-Oct-18 8:30pm GMT

    Full Year 2018 PURE Biosciences Inc Earnings Call

  • Business Wire3 months ago

    PURE Bioscience Reports Fiscal 2018 Year-End Financial Results

    Update on PURE’s SDC-Based Antimicrobial Food Safety Solutions Outlook

  • Business Wire3 months ago

    PURE Bioscience Sets Conference Call to Report 2018 Fiscal Year-End Financial Results

    PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial, announced today that on October 25, 2018 the Company will file its Form 10-K shortly after the close of the market and will host an investor conference call that day at 1:30pm PT (4:30pm ET) to review fiscal 2018 YE financial results. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance.

  • Business Wire3 months ago

    PURE Bioscience Appoints Chief Operating Officer

    PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, announced today that Tom Myers has been promoted to Chief Operating Officer. Myers will be responsible for sales (including the Company’s direct sales force, consultants and growing distributor network), marketing, technical services, operations and engineering. Myers has been with PURE for seven years and for the past two years has served as PURE’s Executive Vice President, Technical Support Services.

  • Business Wire5 months ago

    PURE Bioscience Closes on $1.5 Million Financing and Provides Business Update

    PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, announced today that it has closed on an approximately $1.5 million private placement with existing shareholders. The $1.5 million the company raised includes cancelled indebtedness held by the Company’s director, Tom Y. Lee, of approximately $504,000. The shares were offered and sold pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.

  • TheStreet.com6 months ago

    Small-Cap Cannabis Firms Raise Millions in Growth Cash

    Several micro-cap and private companies in Canada have raised millions this week to boost their cannabis businesses as the industry scales up. The transactions come as Canada prepares for the start in mid-October of legal adult use of recreational marijuana. Market participants told Real Money the flurry of deals fits Canada's tradition of financing emerging businesses through small-cap stock, reverse merger listings and private placements.

  • CNW Group6 months ago

    IIROC Trading Resumption - PURE

    IIROC Trading Resumption - PURE

  • Business Wire7 months ago

    PURE Bioscience Raises $500,000 in Unsecured Promissory Note - Appoints Ivan Chen to Board of Directors

    PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today announced that it has raised $500,000 in the form of a promissory note from Tom Lee, a member of PURE’s Board of Directors and its largest shareholder. Hank R. Lambert, CEO of PURE said, “This non-dilutive interim financing supports our ongoing operations as we continue to expand use by existing customers and garner new users for our SDC-based food safety solutions. PURE also announced that it has named attorney and entrepreneur Ivan Chen to its Board of Directors, filling the vacancy left by the retirement of Director William Otis.

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of PURE earnings conference call or presentation 13-Jun-18 8:30pm GMT

    Q3 2018 PURE Biosciences Inc Earnings Call

  • Business Wire7 months ago

    PURE Bioscience Reports Fiscal 2018 Third Quarter and Nine-Month Financial Results

    PURE Bioscience, Inc. , creator of the patented non-toxic silver dihydrogen citrate antimicrobial, today reported financial results for the fiscal third quarter and nine-month period ended April 30, 2018.

  • Business Wire8 months ago

    PURE Bioscience Sets Conference Call to Report 2018 Fiscal Third Quarter and Nine-Month Financial Results

    PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial, announced today that on June 13, 2018 the Company will file its Form 10-Q shortly after the close of the market and will host an investor conference call that day at 1:30pm PT (4:30pm ET) to review fiscal 2018 Q3 financial results. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance.

  • Business Wire9 months ago

    PURE Bioscience Responds to the Latest Foodborne Illness Outbreak Tied to Romaine Lettuce

    PURE Bioscience, Inc. , creator of the patented silver dihydrogen citrate antimicrobial, today responded to the current widespread foodborne illness outbreak associated with romaine lettuce.

  • Thomson Reuters StreetEvents10 months ago

    Edited Transcript of PURE earnings conference call or presentation 14-Mar-18 8:30pm GMT

    Q2 2018 PURE Biosciences Inc Earnings Call

  • Business Wire10 months ago

    PURE Bioscience Reports Fiscal 2018 Second Quarter and Six-Month Financial Results

    PURE Bioscience, Inc. , creator of the patented non-toxic silver dihydrogen citrate antimicrobial, today reported financial results for the fiscal second quarter and six-month period ended January 31, 2018.

  • ACCESSWIRE10 months ago

    Pure Bioscience, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 14, 2018 / Pure Bioscience, Inc. (NASDAQ: PURE ) will be discussing their earnings results in their Q2 Earnings Call to be held on March 14, 2018, at 4:30 PM Eastern Time. ...

  • OTCQX And OTCQB Companies to Present At 2018 ROTH Conference
    PR Newswire10 months ago

    OTCQX And OTCQB Companies to Present At 2018 ROTH Conference

    OTC Markets Group EVP Jason Paltrowitz to Speak on Panel on "Reg A+ Offerings" NEW YORK , March 8, 2018 /PRNewswire/ -- OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for ...

  • Business Wire11 months ago

    PURE Bioscience Sets Fiscal 2018 Q2 Financial Results Conference Call

    PURE Bioscience, Inc. , creator of the patented, non-toxic silver dihydrogen citrate antimicrobial, announced today that on March 14, 2018 the Company will file its Form 10-Q shortly after the close of the market and will host an investor conference call that day at 1:30pm PT to review fiscal 2018 Q2 financial results.

  • Business Wire11 months ago

    PURE Bioscience Provides Update: Expanding Use of PURE Control® Antimicrobial in Produce Processing; Expanding Use of PURE® Hard Surface Disinfectant

    PURE Bioscience, Inc. , creator of the patented non-toxic silver dihydrogen citrate antimicrobial, provided an update on the expanded use of FDA approved PURE Control® antimicrobial for application directly onto produce during processing and the expanded use of PURE Hard Surface disinfectant.

  • Business Wire11 months ago

    PURE Bioscience to Present at the 30th Annual ROTH Capital Partners Conference

    PURE Bioscience, Inc. , creator of the patented non-toxic silver dihydrogen citrate antimicrobial, announced today that the Company will present at the 30th Annual ROTH Capital Partners Conference on March 12, 2018 in Orange County, CA.